Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Immutep (IMM) doses its first patient suffering from lung carcinoma as part of its INSIGHT-003 study
  • The patient was treated with the company’s lead product, efti, in combination with an existing approved standard of care treatment
  • The study will continue to recruit up to 20 patients with various solid tumours and first results are expected in calendar year 2022
  • Immutep is trading up two per cent at 51 cents at 11:57 am AEST

Immutep (IMM) has dosed its first patient suffering from lung carcinoma as part of its INSIGHT-003 study.

INSIGHT-003 is a trial conducted by the Institute of Clinical Cancer Research IKF in Frankfurt. The trial will involve patients receiving 30 milligrams of subcutaneous doses of eftilagimod alpha (efti) every two weeks.

The biotechnology company enrolled and dosed the patient – who suffers from metastatic non-small cell lung carcinoma – with pembrolizumab plus doublet chemotherapy combined with Immutep’s lead product candidate, efti.  

The study looks to evaluate a triple combination therapy consisting of efti in conjunction with an existing approved standard of care to assess the treatment’s safety, tolerability and initial efficacy of the combination.

“INSIGHT-003 is the first time a triple combination therapy consisting of efti plus anti-PD-1 plus chemo is administered,” Immutep Chief Strategy Officer and Chief Medical officer Frédéric Triebel said.

“We are evaluating how efti might boost an approved chemotherapy and anti-PD-1 combination therapy, looking at safety and initial activity,” Dr Triebel said.

The study will continue to recruit up to 20 patients with various solid tumours and first results are expected in calendar year 2022.

Immutep was trading up two per cent at 51 cents at 11:57 am AEST.  

IMM by the numbers
More From The Market Herald
APM (ASX:APM) - CEO, Michael Anghie

" APM Human Services (ASX:APM) expands, acquiring Lifecare

APM Human Services International (APM) has acquired physiotherapy and home care group Lifecare for $68 million.
Resonance Health (ASX:RHT)

" Resonance Health (ASX:RHT) submits LiverSmart to FDA

Resonance Health (RHT) has submitted its LiverSmart device to the Food and Drug Administration (FDA) for US regulatory clearance.
Dotz Nano (ASX:DTZ) - CEO, Gideon Shmuel

" Dotz Nano (ASX:DTZ) signs Malaysian distribution deal for COVID-19 tests

Dotz Nano (DTZ) has entered into a distribution agreement with ScienceVision to promote, sell and distribute its COVID-19 virus detection technology in Malaysia.
Kazia Therapeutics (ASX:KZA) - CEO, Dr James Garner

" Kazia Therapeutics (ASX:KZA) releases “positive” second-phase study results for brain cancer treatment

Kazia Therapeutics (KZA) has opened the trading day green after reporting positive final results from a second-phase clinical study of its paxalisib drug